Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Phase 3
Completed
NCT05987423
| Condition | Thyroid Eye Disease, TED |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Hoffmann-La Roche |
|---|
| Status | Completed |
|---|
| Enrollment | 131 participants |
|---|
| Interventions | Satralizumab |
|---|
| Start date | Oct 26, 2023 |
|---|
| Completion date | Jul 8, 2025 |
|---|
| Results posted | Jul 31, 2026 |
|---|
Summary
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).
Percentage of Participants in the Active TED Population Who Achieved ≥ 2 Millimeters (mm) Reduction in Proptosis From Baseline at Week 24 in the Study Eye
At Week 24 · percentage of participants
| Part I: Satralizumab | 49.0 percentage of participants |
|---|
| Part I: Placebo | 31.2 percentage of participants |
|---|
| p-value | 0.0715 |
|---|
| Difference in Response Rates at Week 24 | 17.9 (95% CI -1.6–37.3) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.